Recently, deregulated activity of the NF-κB signaling pathway due to genetic mutations emerged as a major driver in the pathogenesis of several B-lineage malignancies, especially in aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL) and in multiple myeloma (MM), an incurable tumor of PCs. This evidence concerns the gene NFKB1 and plasma cell myeloma.